Automated Cell Culture Market Analysis

Product Type (Consumables, Equipment)

The equipment segment share in the automated cell culture market is expected to reach 61% by 2037. Equipment for automated cell culture is designed to streamline and expedite any cell culture process. Because automated cell culture instruments perform the necessary duties to establish and maintain a cell culture mechanically, they are used in laboratories. Automated cell culture equipment can perform several activities, such as plating cultures, dilution of samples, continuous spinning of cultures in liquid culture, and well-depositing of cultures. Because automated cell culture systems can generate the best cell lines over the whole range of seeding, feeding, massaging, and cell multiplication, their popularity has grown. They help achieve high standards and criteria while reducing human error. The need for automated cell culture equipment is growing as high-throughput cell lines are used in more drug discovery studies.

End User (Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Research & Academic Institutes)

Automated cell culture market from the pharmaceutical & biotechnology companies segment is expected to hold 45% revenue share by 2037.  Over the course of the projected period, the pharmaceutical and biotechnology businesses segment is anticipated to keep the majority share. The growing prevalence of chronic illnesses and the growth of research and development in the biotechnology and pharmaceutical industries are factors contributing to this sector's sizeable market share. Furthermore, the expanding network of biopharmaceuticals and biotech companies will propel segmental expansion. FUJIFILM Diosynth Biotechnologies, for example, celebrated the launch of its USD 2 billion large-scale cell culture manufacturing facility in November 2023. When completed, the new building will house state-of-the-art biopharmaceutical manufacturing technology and be the largest CDMO in North America. The new building will serve as a key component of FUJIFILM Diosynth Biotechnologies' global network for the production of biopharmaceuticals for major US and European customers.

Our in-depth analysis of the global market includes the following segments: